Acadian Asset Management
TBPH icon

Acadian Asset Management’s Theravance Biopharma TBPH Stock Holding History

Acadian Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20M Sell
1,174,910
-101,666
-8% -$1.68M 0.02% 425
2026
Q1 		$20.7M Buy
1,276,576
+110,617
+9% +$1.96M 0.03% 375
2025
Q4 		$21.8M Buy
1,165,959
+76,578
+7% +$1.27M 0.04% 320
2025
Q3 		$15.9M Buy
1,089,381
+780,729
+253% +$9.87M 0.03% 372
2025
Q2 		$3.4M Buy
308,652
+134,058
+77% +$1.3M 0.01% 684
2025
Q1 		$1.55M Buy
174,594
+174,451
+121,994% +$1.62M ﹤0.01% 824
2024
Q4 		$1K Sell
143
-69,166
-100% -$629K ﹤0.01% 1581
2024
Q3 		$557K Buy
+69,309
New +$600K ﹤0.01% 1060
2022
Q2 		– Sell
-8,277
Closed -$77K – 1853
2022
Q1 		$77K Buy
8,277
+2,818
+52% +$27.6K ﹤0.01% 1413
2021
Q4 		$60K Sell
5,459
-43,843
-89% -$382K ﹤0.01% 1461
2021
Q3 		$362K Buy
+49,302
New +$551K ﹤0.01% 1140

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management's TBPH Position: Q2 2026 in Review

Acadian Asset Management reduced its Theravance Biopharma (TBPH) stake by 8% in Q2 2026, selling an estimated $1.68M and leaving 1,174,910 shares worth $20M. The position accounts for 0.02% of the portfolio, ranked #425.

Acadian Asset Management first reported a position in TBPH in Q3 2021 and has held it in 11 quarters since. The position peaked at $21.8M in Q4 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Acadian Asset Management held 1,174,910 shares of Theravance Biopharma worth $20M as of Q2 2026.
  • Acadian Asset Management sold 101,666 Theravance Biopharma shares in Q2 2026, an estimated $1.68M.
  • Theravance Biopharma made up 0.02% of Acadian Asset Management's portfolio in Q2 2026, its #425 holding.
  • Acadian Asset Management first reported a position in Theravance Biopharma in Q3 2021 and has held it in 11 quarters since.
  • Acadian Asset Management's Theravance Biopharma position peaked at $21.8M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.